Corticosteroid-Induced Regression of Glioblastoma: A Radiographic Conundrum

Joshua A. Cuoco 1,2,3,4*, Brendan J. Klein 1,2,3,4, Christopher M. Busch 1,2,3,4, Evin L. Guilliams 1,2,3,4, Adeolu L. Olasunkanmi 1,2,3,4 and John J. Entwistle 1,2,3,4

1 Section of Neurosurgery, Carilion Clinic, Roanoke, VA, United States, 2 Virginia Tech Carilion School of Medicine, Roanoke, VA, United States, 3 Virginia Tech School of Neuroscience, Blacksburg, VA, United States, 4 Edward Via College of Osteopathic Medicine, Blacksburg, VA, United States

Corticosteroid-induced regression of lesion contrast enhancement on imaging studies is most commonly appreciated with primary central nervous system lymphoma; however, although exceedingly rare, a limited number of primary and metastatic intracranial lesions have been reported to exhibit similar radiographic changes subsequent to corticosteroid therapy. To date, there have been six cases of glioblastoma reported to exhibit such changes. Lesion transformation on repeat imaging after the initiation of steroids represents a diagnostic dilemma for clinicians when attempting to differentiate between a diagnosis of glioblastoma and lymphoma. Stereotactic biopsy may be inadvertently postponed due to high clinical suspicion for steroid-induced cytotoxicity traditionally seen with lymphomatous cells. To highlight this radiographic conundrum, we present a rare case of corticosteroid-induced regression of glioblastoma and discuss the relevant literature. To our knowledge, this is the first case report to describe the molecular profile of a glioblastoma that underwent corticosteroid-induced regression.

Keywords: glioblastoma, astrocytoma, brain tumor, corticosteroid, dexamethasone, regression, vanishing tumor, neuro-oncology

BACKGROUND

Glioblastoma is the most common malignant brain tumor in adults with an estimated incidence of 2–3 cases per 100,000 persons worldwide (1). Despite surgical resection followed by adjuvant radiotherapy and chemotherapy, long-term survival from glioblastoma remains dismal with a median survival time of 1 year (1). Radiographically, glioblastoma typically presents as a solitary infiltrative supratentorial lesion with intense peripheral contrast enhancement, a variable degree of central necrosis, and surrounding vasogenic edema. On the contrary, primary central nervous system lymphoma (PCNSL) in an immunocompetent host appears as a supratentorial periventricular lesion with vivid homogeneous enhancement without central necrosis and a variable degree of vasogenic edema. Nevertheless, these lesions can often appear similar on routine morphological magnetic resonance imaging (MRI) emphasizing the necessity for definitive tissue diagnosis to establish appropriate treatment options.
Patients who harbor intracranial lesions are typically given a course of corticosteroids to reduce peritumoral edema and relieve associated neurologic symptomatology. Contrary to PCNSL, glioblastoma is not known to routinely undergo radiographic transformation after the initiation of systemic corticosteroid treatment. However, corticosteroid-induced regression of glioblastoma is a rare but documented phenomenon with six cases reported since first described in 1997 (2–6). Radiographic changes in glioblastoma following corticosteroid therapy demonstrate a diagnostic conundrum for clinicians as biopsy may be delayed due to clinical suspicion for PCNSL. Here, we present an atypical case of a 76-year-old immunocompetent male found to have a heterogeneous peripherally enhancing lesion of the right parietal lobe on imaging that underwent corticosteroid-induced regression on repeat pre-operative imaging 4 weeks later. Stereotactic biopsy revealed a histologic diagnosis of glioblastoma. To our knowledge, this is the first case report to describe the molecular profile of a glioblastoma that underwent corticosteroid-induced regression.

CASE PRESENTATION

A 76-year-old immunocompetent Caucasian male presented to the emergency department with 1 week of left hand clumsiness. Physical examination was consistent with mild left upper extremity neglect but otherwise benign. The patient had no relevant past medical history. Computed tomography (CT) scan demonstrated a large hypodense lesion in the right parietal lobe suspicious for neoplasm (Figures 1A,B). Subsequently, MRI revealed a heterogeneous thick-walled peripherally enhancing lesion of the right parietal lobe with central necrosis and an extensive degree of surrounding vasogenic edema (Figures 2A–E). Neither T1-weighted imaging nor gradient echo sequences demonstrated evidence of subacute hemorrhage. Initial differential diagnosis included glioblastoma, anaplastic astrocytoma, metastasis, or PCNSL. A metastatic workup was negative. The patient was started on dexamethasone (16 mg per day for 5 days) while hospitalized with improvement in his presenting neurologic symptomatology. Upon discharge, he was prescribed a 6-day dexamethasone taper to 1 mg per day to continue until outpatient follow up. Per patient preference, stereotactic debulking of the lesion was scheduled for 5 weeks from his initial presentation.

The patient was admitted to the hospital 4 weeks later (1 week prior to scheduled surgery) with new onset lethargy and respiratory distress. Repeat CT compared to 4 weeks prior revealed a dramatic reduction in contrast enhancement, vasogenic edema, and apparent size of the lesion (Figures 1C,D). The patient was diagnosed with bacterial pneumonia and remained hospitalized for medical treatment and optimization. One week later, a repeat MRI was ordered to evaluate the significant changes seen on repeat CT as well as to determine extent of future operative intervention. Repeat MRI compared to 5 weeks prior revealed a dramatic reduction in contrast enhancement, vasogenic edema, and apparent size of the lesion (Figures 2F–J). These imaging findings raised suspicion for PCNSL. As such, a stereotactic biopsy was planned to attain tissue diagnosis. Biopsy samples were sent as frozen sections to surgical pathology, which revealed pleomorphic glial cells, nuclear atypia, microvascular proliferation, and palisading necrosis consistent with a diagnosis of glioblastoma (Figure 3). The decision was then made to proceed with debulking of the tumor.

Molecular genetic studies revealed wildtype isocitrate dehydrogenase (IDH) 1 and 2, promoter methylation of O\textsuperscript{6}-methylguanine DNA methyltransferase (MGMT), non-amplified epidermal growth factor receptor (EGFR) by fluorescence in situ hybridization, and poor p53 expression with 1% tumor cell staining on immunohistochemistry. Adjuvant radiotherapy and chemotherapy were planned to start 3 weeks post-operatively. However, the patient developed worsening lethargy and fatigue 2 weeks after his operation. Post-operative imaging was unrevealing for acute intracranial pathology (Figure 4). Infectious workup remained negative; however, he failed to improve clinically. As such, his clinical demise was attributed to rapid disease progression of recently diagnosed glioblastoma. He was transferred to hospice care and expired 1 month from the date of initial surgery.

Abbreviations: PCNSL, primary central nervous system lymphoma; MRI, magnetic resonance imaging; CT, computed tomography; IDH, isocitrate dehydrogenase; MGMT, O\textsuperscript{6}-methylguanine DNA methyltransferase; EGFR, epidermal growth factor receptor.
FIGURE 2 | MRI of the brain pre- and post-corticosteroid therapy. (A) Initial T1-weighted imaging without evidence of subacute hemorrhage. (B–D) Initial MRI MP-RAGE sequences of the brain pre-corticosteroid therapy demonstrated a thick-walled peripherally enhancing lesion of the right parietal lobe with central necrosis and extensive surrounding vasogenic edema. (E) Initial gradient echo sequence without evidence of subacute hemorrhage. (F) Repeat T1-weighted imaging without evidence of subacute hemorrhage. (G–I) Repeat MRI MP-RAGE sequences of the brain 5 weeks after post-corticosteroid therapy demonstrated reduction in contrast enhancement, vasogenic edema, and apparent size of the lesion. (J) Repeat gradient echo sequence without evidence of subacute hemorrhage.

FIGURE 3 | Histopathology demonstrating pleomorphic glial cells, nuclear atypia, palisading necrosis, mitoses, and vascular proliferation consistent with a diagnosis of glioblastoma. (A,B) Palisading necrosis at 4x and 10x magnification, respectively. (C) Mitoses at 40x magnification. (D) Vascular proliferation at 10x magnification.

DISCUSSION

Corticosteroid-induced regression on imaging is a feature most commonly associated with PCNSL; however, this characteristic has also been reported in cases of metastatic renal cell carcinoma, medulloblastoma, and glioblastoma (2–8). It is thought that corticosteroids cause lymphomatous neoplasms of the brain to undergo rapid cell cycle arrest and cell death, most notably via a p38 mitogen-activated protein kinase-dependent mechanism in T and B cells (9–11). Contrary to PCNSL, corticosteroids do not exhibit tumoricidal effects against glioblastoma nor do they considerably alter their size; rather, dexamethasone decreases vasogenic edema associated with glioblastoma via reducing the permeability of capillaries within the blood brain barrier (12). Corticosteroids can significantly reduce neurologic symptomatology associated with glioblastoma as some studies have shown a 1-week course of corticosteroids to reduce peritumoral edema by as much as 50%.
| Years | Author | Age/Sex | Multicentric | Original location(s) | Radiographic change | Time to reappearance | Location of reappearance | Dexamethasone dose | Treatment | Clinical outcome | Molecular profile | References |
|-------|--------|---------|--------------|---------------------|---------------------|---------------------|------------------------|---------------------|-----------|-----------------|------------------|------------|
| 1997  | Buxton et al. | 56 M | No | Left frontoparietal | Disappearance of lesion and enhancement | 3 weeks | Same | 6 mg per day, unspecified duration | None | Death immediately | NR | (2) |
| 2004  | Zaki et al. | 53 M | Yes | Right parietal, splenium | Reduced enhancement in parietal lesion, increased splenial enhancement | 3 weeks | Same | 16 mg per day for 3 weeks | Radiotherapy | NR | NR | (3) |
| 2004  | Zaki et al. | 75 M | Yes | Right parietal, splenium | Reduced enhancement in parietal lesion, increased splenial enhancement | 3 weeks | Splenium only | 16 mg per day for 3 weeks | None | Death before radiation, unspecified timing | NR | (3) |
| 2009  | Hasegawa et al. | 59 M | No | Left parietal | Reduced enhancement | 4 weeks | Same | 16 mg per day for 4 weeks | NR | NR | NR | (4) |
| 2009  | Goh et al. | 61 F | Yes | Right temporal, splenium | Near resolution of all lesions | 4 weeks | Same plus new right frontal lesion | 16 mg per day for 4 weeks | Radiotherapy | Death ~4 months after reappearance | NR | (5) |
| 2012  | Mazur et al. | 57 F | No | Right temporoparietal extending into splenium | Reduced enhancement | 2 weeks | Same plus leptomeningeal carcinomatosis | 16 mg per day for 5 days | Radiotherapy, temozolomide | Alive 2 months after radiographic change | NR | (5) |
| 2019  | Cuoco et al. | 76 M | No | Right parietal | Reduced enhancement | N/A | N/A | 16 mg per day for 5 weeks tapered | None | Death 1 month after surgery | Wildtype IDH1/2 Methylated MGMT Non-amplified EGFR Poor p53 expression | (2) |

M, male; NR, not reported; F, female; N/A, not applicable; IDH, isocitrate dehydrogenase; MGMT, O\textsubscript{6}\textsuperscript{-}methylguanine DNA methyltransferase; EGFR, epidermal growth factor receptor.
Although corticosteroids reduce apparent tumor volume, MRI volumetric studies have demonstrated this reduction to be restricted to vasogenic edema with tumor size remaining relatively constant (14).

Corticosteroid-induced regression of glioblastoma is an exceedingly rare phenomenon. Indeed, our literature search revealed only six cases of this entity since first reported in 1997 (Table 1) (2–6). Buxton et al. first described a case of a disappearing frontoparietal glioblastoma in a 56-year-old male after a short course of dexamethasone (6 mg per day, unspecified duration) (2). Pre-operative imaging 3 weeks thereafter demonstrated disappearance of the lesion. The patient was taken off dexamethasone and biopsy was rescheduled for 3 weeks later. Repeat imaging demonstrated reappearance of the frontoparietal lesion consistent with radiographic characteristics seen in PCNSL. However, biopsy confirmed a histopathologic diagnosis of glioblastoma. In 2004, Zaki et al. described two similar cases of multicentric glioblastoma, both of which demonstrated lesions in the right parietal lobe and splenium of the corpus callosum (3). Repeat imaging after a course of dexamethasone (16 mg per day for 3 weeks) revealed reduced contrast enhancement in the parietal lesions with increased enhancement within the splenial lesions in both cases. These patients were taken off dexamethasone and repeat imaging was ordered for 3 weeks later. One case demonstrated reappearance of both lesions whereas the second case demonstrated reappearance of only the splenial lesion. Similarly, Goh et al. reported a case of multicentric glioblastoma with lesions in the right temporal lobe and splenium; however, after cessation of dexamethasone, a new focus of contrast enhancement within the right frontal lobe was demonstrated in addition to reappearance of the original lesions (5). Moreover, Mazur et al. described reappearance of a temporoparietal lesion with new onset leptomeningial carcinomatosis after cessation of dexamethasone (6). In their report, the authors described the reduction in lesion enhancement followed by lesion reappearance after stopping dexamethasone as corticosteroid-induced “pseudoregression.”

Collectively, the mean age at time of diagnosis in these six cases was 60.2 years (range: 53–75 years) with a slight male predilection (4 of 6 cases). Half of the cases reported multicentric glioblastoma. The parietal lobe was the most common original location of glioblastoma involved in 5 of 6 cases. The average duration of dexamethasone therapy was 2.9 weeks (range 5 days–4 weeks) with the majority of cases prescribing 16 mg per day. Overall, clinical outcome documented in 4 of 6 cases was dismal with the longest documented survival time reported to be 4 months from lesion reappearance on imaging. With the most recent case published in 2012, none of these cases documented results of molecular genetic studies. The case we present has similar epidemiologic and clinical characteristics as those previously reported including age (76 years old vs. a mean of 60.2 years old), sex predilection (male), original location of the tumor (parietal lobe), and clinical outcome (death only months after surgery). Contrary to the cases described in prior, we chose to pursue stereotactic biopsy immediately after repeat imaging despite reduced lesion enhancement in order to attain tissue diagnosis and expedite treatment options (2–6). Molecular genetic studies from our case revealed wildtype IDH1/2, methylated MGMT, non-amplified EGFR, and poor p53 expression. These data establish the first molecular profile of a glioblastoma that underwent corticosteroid-induced regression.

With the exception of PCNSL, the only other primary intracranial lesion, to our knowledge, that has been reported to exhibit corticosteroid-induced regression is a case of a medulloblastoma described by Gupta et al. (8). The authors described a 17-year-old female with a poorly defined contrast-enhancing lesion within the posterior fossa with associated hydrocephalus and effacement of the fourth ventricle (8). The patient was started on dexamethasone (12 mg per day for 2 weeks) and underwent a single fraction of radiotherapy (8 Gy). Three weeks later, a suboccipital craniectomy was performed for planned tumor resection; however, despite multiple biopsies, no tumor or inflammatory lesion was identified. Post-operative CT was without evidence of the lesion. Follow up imaging 5 months later revealed a heterogeneously enhancing lesion within the left cerebellar hemisphere with cystic and solid components. Biopsy was repeated and histopathology confirmed a diagnosis of medulloblastoma. Similar to the majority of intracranial lesions, medulloblastoma is not subject to steroid-induced toxicity nor are these lesions known to exhibit radiographic changes on subsequent imaging after the initiation of steroids. This case illustrates that corticosteroids should be stopped and repeat imaging should be obtained if a lesion cannot be localized macroscopically via open craniotomy or diagnosed microscopically via frozen pathology.

CONCLUSIONS

As depicted by the present case and prior reports, the degree of glioblastoma regression with dexamethasone can be substantial and confound diagnostic clinical suspicion. As such, this case not only illustrates the importance in obtaining a contrast-enhanced CT or MRI scan in a reasonably close timeframe to performing neurosurgical intervention but also emphasizes the necessity in acquiring tissue diagnosis for intracranial lesions that transform in appearance on imaging studies. Indeed, pathologic diagnosis is crucial as corticosteroid-induced changes can represent steroid-induced tumor cytotoxicity in PCNSL or a rare unknown transformative process in glioblastoma. In order to better understand their natural history, the molecular profile of glioblastoma that regress with corticosteroid therapy must be established.

ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
AUTHOR CONTRIBUTIONS

JC: primary author of manuscript. JC, BK, CB, EG, AO, and JE: provided substantial contributions to the conception and design of the manuscript, contributed to manuscript revision, read and approved the submitted version, and agree to be accountable for all aspects of the work ensuring that questions related to the accuracy or integrity of any part of the work are investigated and resolved.

REFERENCES

1. Xu H, Chen J, Xu H, Qin Z. Geographic variations in the incidence of glioblastoma and prognostic factors predictive of overall survival in US adults from 2004–2013. Front Aging Neurosci. (2017) 9:352. doi: 10.3389/fnagi.2017.00352
2. Buxton N, Phillips N, Robertson I. The case of the disappearing glioma. J Neurol Neurosurg Psychiatry. (1997) 63:520–521. doi: 10.1136/jnnp.63.4.520
3. Zakri S, Jenkinson MD, Du Plessis DG, Smith T, Rainov NG. Vanishing contrast enhancement in malignant glioma after corticosteroid treatment. Acta Neurochir. (2004) 146:841–5. doi: 10.1007/s00701-004-0282-8
4. Hasegawa H, Pal D, Ramirez R, Ismail A, Marks P. Glioblastoma multiforme fades on CT imaging after dexamethasone therapy. J Clin Neurosci. (2009) 16:1707–8. doi: 10.1016/j.jocn.2009.02.024
5. Goh JJ, See SJ, Ang E, Ng WH. Vanishing glioblastoma after corticosteroid therapy. J Clin Neurosci. (2009) 16:1226–8. doi: 10.1016/j.jocn.2008.10.029
6. Mazur MD, Nguyen V, Fults DW. Vanishing glioblastoma presenting with steroid-induced pseudoregression of contrast enhancement on magnetic resonance imaging. Case Rep Neurol Med. (2012) 2012:816873. doi: 10.1155/2012/816873
7. Bromberg JE, Siemers MD, Taphoorn MJ. Is a “vanishing tumor” always a lymphoma? Neurology. (2002) 59:762–4. doi: 10.1212/WNL.59.5.762
8. Gupta V, Kumar S, Tatke M, Singh AK, Sinha S, Singh D. Disappearing cystic cerebellar medulloblastoma: the ghost tumour. Neurol India. (2001) 49:291–4.
9. Roth P, Hapgood C, Weller M. Corticosteroid use in neuro-oncology: an update. Neurooncol Prac. (2015) 2:6–12. doi: 10.1093/np/nuo029
10. Krohn K, Grubbauer C, Goetsch K, Jakel H, Podmirseg SR, Trockenbacher A, et al. The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells. Cell Cycle. (2013) 12:2625–35. doi: 10.4161/cc.25622
11. Sionov RV, Spokoini R, Kfir-Erenfeld S, Cohen O, Yelenof E. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Adv Cancer Res. (2008) 101:127–248. doi: 10.1016/S0065-230X(08)0406-5
12. Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol. (2011) 4:233–42. doi: 10.1586/ecp.11.1
13. Andersen C, Astrup J, Gyldensted C. Quantitation of peritumoral oedema and the effect of steroids using NMR-relaxation time imaging and blood-brain barrier analysis. Acta Neurochir Suppl. (1994): 60:413–415. doi: 10.1007/978-3-7091-9334-1_112
14. Galloway RL Jr, Maciunas RJ, Failing AL. Factors affecting perceived tumor volumes in magnetic resonance imaging. Ann Biomed Eng. (1993) 21:367–75. doi: 10.1007/BF02368629

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor declared a past supervisory role with one of the author JC.

Copyright © 2019 Cuoco, Klein, Busch, Guilliams, Olasunkanmi and Entwistle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.